Fibnib 150mg Soft Gelatin Capsule belongs to the category of 'anti-fibrotic medicine', and it is primarily used to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF is an irreversible disease marked by a progressive decline in lung function. The tissues in the lungs become swollen and scarred over time, which makes it difficult to breathe deeply. The scarring makes it hard for the lungs to work properly.

Fibnib 150mg Soft Gelatin Capsule contains 'Nintedanib', which helps reduce the scarring and swelling in the lungs by decreasing the release/activity of naturally occurring growth factors in the body, allowing you to breathe better. Fibnib 150mg Soft Gelatin Capsule helps in slowing down the progress of idiopathic pulmonary fibrosis.

Always use this medicine as your doctor has told you or per the package leaflet. You must keep to your doctor's instructions to get the maximum benefit. In some cases, you may experience common side effects such as nausea, tiredness, diarrhoea, indigestion, loss of appetite, headache, and photosensitivity. Most of these side effects do not require medical attention and will resolve gradually over time. However, you are advised to talk to your doctor if you experience these side effects persistently.

Consult your doctor before taking Fibnib 150mg Soft Gelatin Capsule if you are pregnant or breastfeeding. Fibnib 150mg Soft Gelatin Capsule may cause tiredness and dizziness, so drive with caution. Avoid consuming alcohol with Fibnib 150mg Soft Gelatin Capsule as it could lead to increased dizziness. Fibnib 150mg Soft Gelatin Capsule is not recommended for children below 18 years as safety and effectiveness have not been established. Fibnib 150mg Soft Gelatin Capsule is listed as pregnancy category D. Because Fibnib 150mg Soft Gelatin Capsule can cause harm to the fetus, women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Fibnib 150mg Soft Gelatin Capsule. Consult your doctor if you are breastfeeding; your doctor will decide whether the Fibnib 150mg Soft Gelatin Capsule can be taken by breastfeeding mothers or not. Keep your doctor informed about your health condition and medicines to rule out any side effects.

Fibnib 150mg Soft Gelatin Capsule is an anti-fibrotic medicine used to treat idiopathic pulmonary fibrosis (IPF) in adults. Fibnib 150mg Soft Gelatin Capsule can help effectively slow the rate of lung function decline by 50%. Fibnib 150mg Soft Gelatin Capsule helps reduce the scarring and swelling in the lungs by decreasing the release/activity of naturally occurring growth factors in the body, allowing you to breathe better. Fibnib 150mg Soft Gelatin Capsule helps in slowing down the progress of idiopathic pulmonary fibrosis.

• Diarrhoea
• Feeling and being sick
• Tummy (Abdominal) Pain
• Loss of appetite and weight loss

Do not use Fibnib 150mg Soft Gelatin Capsule if you are allergic to any components present in Fibnib 150mg Soft Gelatin Capsule. Fibnib 150mg Soft Gelatin Capsule is listed as pregnancy category D; because Fibnib 150mg Soft Gelatin Capsule can cause harm to the fetus, women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Fibnib 150mg Soft Gelatin Capsule. Consult your doctor if you are breastfeeding; your doctor will decide whether the Fibnib 150mg Soft Gelatin Capsule can be taken by breastfeeding mothers or not. Keep your doctor informed about your health condition and medicines to rule out any side effects. Fibnib 150mg Soft Gelatin Capsule may cause tiredness and dizziness, so drive with caution. Avoid consuming alcohol with Fibnib 150mg Soft Gelatin Capsule as it could lead to increased dizziness. Fibnib 150mg Soft Gelatin Capsule is not recommended for children below 18 years as safety and effectiveness have not been established.

Drug-Drug Interactions: Fibnib 150mg Soft Gelatin Capsule may have interaction with medicines used to treat fungal infections (e.g. ketoconazole), medications used to treat bacterial infections/CYP3A4 inhibitors (e.g. erythromycin), drugs that affect your immune system (e.g. cyclosporine), antibiotic medicines used to treat tuberculosis (e.g. rifampicin), medicines to treat seizures (e.g. carbamazepine, phenytoin), and herbal medicines to treat depression (e.g. St. John’s Wort).

Drug-Food Interactions: Avoid grapefruit juice and chargrilled meats.

Drug-Disease Interactions: Fibnib 150mg Soft Gelatin Capsule may interact with smoking and severe hepatic and end-stage renal impairment requiring dialysis.

• KETOCONAZOLE
• ERYTHROMYCIN
• CYCLOSPORINE
• RIFAMPICIN
• CARBAMAZEPINE
• PHENYTOIN

• Watch out for triggers that worsen the cough, such as smoke, foods, air-conditioning, high altitude, etc.
• Exercise moderately. Eat healthily.
• Follow pulmonary rehabilitation program. It includes exercise, disease education, and group therapy.
• Quit smoking and alcohol.
• Get ample rest.
• Include green leafy vegetables, sweet potatoes, broccoli, tomatoes, carrots, mangoes, citrus fruits, berries, and cocoa.
• Lean proteins such as fish, meat, and poultry are the best.
• Hydration is important. Drink plenty of water, herbal tea, and vegetable and fruit juices.
• Avoid processed and refined foods.

• Regular blood tests and occasional tests of your bone marrow will be carried out to check whether the treatment is working. If it does work, it will usually be taken for life.

Idiopathic pulmonary fibrosis (IPF): Idiopathic pulmonary fibrosis belongs to a group of interstitial lung diseases. It is an irreversible chronic disease marked by a progressive decline in lung function. The tissues in the lungs become inflamed and scarred over time, due to which it gets difficult to breathe properly. The scar tissue, known as fibrosis, becomes thick /stiff over time, making it hard for the lungs to work efficiently. This causes decreased lung function, which leads to increased breathlessness and coughing. Breathing difficulties can lead to other medical problems. Symptoms of IPF are shortness of breath, persistent dry cough, loss of appetite, weight loss, and rounded and widened tips of the fingers and toes.